The goal of investors is to create long-term shareholder value in the companies in which they invest. This potential is maximized by investing in well-managed, high quality companies, where the management team have considered fully the range of business risks and opportunities facing their companies, and taken appropriate action to manage these. Alongside assessment of traditional financial risks and opportunities, there is growing recognition among the investment community of the potential for environmental, social and governance (ESG) factors to impact the financial performance of companies. As such, investors are also seeking for companies to demonstrate effective management of ESG factors.

We believe the issue of access to medicine in developing countries can present potentially significant business impacts for global companies in the pharmaceutical sector. As greater emphasis is placed on accessing new markets as a source for future industry growth, pharmaceutical companies are brought into ever closer contact with access to medicine issues in developing countries. Mismanagement of these issues can impact negatively on political relationships and corporate brands and encumber market access. On the other hand, if pharmaceutical companies act responsibly and with foresight, commercial potential can be unlocked.

As investors, we seek assurances that the management of the companies in which we invest have fully considered the risks and opportunities of this issue, and have effective policies and processes for dealing with the challenges. By taking management of this issue into account, alongside other key ESG and financial issues, the investment community can better assess the long-term investment value of such companies. We are increasingly reviewing corporate approaches to access to medicine and associated aspects of intellectual property as a key strategic consideration in our analysis of the sector, where this is appropriate to do so.

It is in this context that the investors listed below welcome the development of analytical tools such as the Access to Medicine Index, which may be used by investors to assess companies’ management of the issue, based on information obtained from their reporting activities.

By our explicit inclusion in this statement, we are agreed on the following:

- We believe the issue of access to medicine is potentially material to long-term shareholder value creation, and is a potentially relevant consideration when forming views on the strategic positioning of companies in the pharmaceutical sector. We welcome the Access to Medicine Foundation’s efforts to develop a credible, transparent and independent tool, which could be useful with regards to specific issue;
- We consider that pharmaceutical companies have an important role to play in addressing the access to medicine issue;
- We will review and take into account the analysis generated from the Index as appropriate in the ESG analysis we conduct on the companies we invest in;
- We hope that the Index will contribute towards creating greater awareness within the industry of this important issue, and act as a tool for highlighting leadership and good practice, as well as gaps and challenges;
- We will provide investor input into the evolution of the Index to ensure it considers the investment perspective as appropriate and remains dynamic and relevant to the debate.

We would encourage other investors to join us in this statement.
TOTAL ASSETS UNDER MANAGEMENT IN EXCESS OF USD 20 TRILLION

For more information please contact Mara Lilley
mlilley@accessomedicinefoundation.org
+31 (0) 20 21 53 535
Abertdeen Standard Investments Andrew Mason
Achmea Jeroen Wieneckx
ACTIAM Collette Grosscutt
Adrian Dominican Sisters Donna Meyer
Aegon Nederland N.V. Willem Horstmann
Aerox and Hexavest Arnaud Celka
Alecta Peter Loow
American Century Investments Guillaume Mascotto
AMP Capital Emily Woodland
Amundi Asset Management Caroline Le Meaux
APG Asset Management Els Knoope
AS/NZ Beleggingsfondsen Piet Sprengers
ASR Nederland N.V. Jack Julicher
Asset Management One Toru Terasawa
Auriga Partners Jacques Chatin
Australian Ethical Investment Stuart Palmer
Aviva Investors Steve Waygood
AXA Investment Managers Gilles Moec
BancoPosta Fondi S.p.A. SGR Stefano Giuliani
BM Global Asset Management Catherine McCabe
BNP Paribas Investment Partners Helena Vines Fiestas
Bon Secours Mercy Health Donna Meyer
Boston Common Asset Management Lauren Compere
Boston Trust Geldbank Company Heidi Soumerai
Calvert Research and Management Stuart Dalheim
Candriam Investors Group Sophie Deleuze
Castlefield Investment Partners Mark Elliot
CCLA Investment Management Amy Browne
Central Finance Board of the Methodist Church Christophe Borysiewicz
Church of Sweden Sara Nordbrand
ClearBridge Investments Marshall Gordon
Coho Partners Nimrit Kang
Cometa Pension Fund Maurizio Agazzi
Congest Sebastien Thevoux-Chabuel
Cooperatie VGZ UA Erik Jan van Bergen
C-QUADRAT Asset Management GmbH Günther Kastner
Credit Mutuel Asset Management Isabelle Delattre
CZ Fund Management BV Yvo Boon
Dana Investment Advisors Ann Roberts
Daughters of Charity, Province of St. Louise Donna Meyer
Dignity Health Donna Meyer
Domiini Impact Investments LLC Carolie Lebound
ECO Advisors Roz Yazdan
Ecofi Investimentos Francois Lett
EdenTree Investment Management Ketan Patel
Edmond de Rothschild Asset Management (France) Adeline Salat-Baroux
EFG Asset Management Stefano Montobbio
EGAMO Jérôme Tendeau
Epworth Investment Management Christophe Borysiewicz
Ethical Partners Funds Management Robyn Parkin
Ethos Vincent Kaufmann
Etica Sgr - Responsible Investments Luca Mattiazz
Federated Hermes Kimberley Lewis
Forma Futura AG Doris Hauser
GAM Investments Mark Harland
Groupama AM Jana Celeste
Groupe MACSF Luc Deschamps
Harmonie Mutuelle Aurelien Bon
Hexavest Jo-Annie Pinto
Ibercaja Gestión Mirian Fernández Jiménez
ICCR Meg Jones-Monteiro
Impax Asset Management and Pax World Funds Evie Paterson
Indecap Mats Lagerqvist
J. Safra Sarasin Nico Frey
Janus Henderson Antony Marsden
Jennison Associates LLC Linda Galsim
JLens Investment Network Rabbi Joshua Ratner

Joh. Berenberg, Gossler & Co. KG Dr. Rupini Rajagopalan
Kempen Capital Management Eszter Vitorino
La Banque Postale Asset Management Luisa Florez
La Financiere de l’Echiquier Coline Pavet
Länsförsäkringar AB Kristofer Dreiman
Legal & General Investment Management Maria Larsson Ortino
Local Government Super Moya Yip
MG&G Investments Ben Constable Maxwell
Mercy Investment Services Donna Meyer
Miller/Howard Investments Luan Steinhilber
Mirova Manon Salomez
MN Louis Kravenburg
Natixis Marina Iodice
NEL Investments Jamie Bonham
NN Investment Partners Adrie Heinslaak
Nomura Asset Management Toshiyuki Imamura
Nordea Asset Management Magdalena Kettis
Northwest Coalition for Responsible Investment Judy Byron
OFI Asset Management Eric Van La Beck
Ohman Fredric Nystrom
Parnassus Investments Benjamin Allen
Pax World Funds Joe Keefe
Pensioenfonds Medewerkers Apothekers (PMA) Remco Velasquez
PGGM Rogier Snijdewind
Poste Vita S.p.A. Antonio Colombi
Quaestio Capital GrS Spa Mario Baroni
RAM Active Investments SA Cyrille Joyce
Rathbone Greenbank Investments Matt Crossman
Reynolds, McVeigh Capital Management, LLC Maria Egan
Robeco Peter van der Werf
Royal London Asset Management Ashley Claxton
Schoriders Seema Suchak
SEB Investment Management AB Anette Andersson
SPH Bram Stageman
SPPS Marcel Roberts
Stewart Investors Jennifer Stephen
Stichting Algemeen Pensioenfonds Unie
Storingen ver Nederland
Storebrand Asset Management Matthew Smith
Sumitomo Mitsui Trust Asset Management Seiji Kawaoze
Swedbank Robur Fonder AB Pia Gissjård
Symcoore Asset Management Bertille Knuckey
T. Rowe Price Maria Elena Drew
The Congregation of St. Joseph Donna Meyer
The Dai-ichi Life Insurance Company, Limited Hiroko Ishii
The Sisters of St. Francis of Philadelphia Nora Nash
The Socially Responsible Investing Group of 1919 Investment Counsel Alison Bevilacqua
The Sustainability Group of Loring, Wolcott & Coolidge Larisa Ruoff
Tokio Marine Asset Management Co., Ltd. Yo Mizuno
Trillium Asset Management Jonas Kron
Trinity Health Cathy Rowan
Triodos Investment Management Erik Breen
Trustee Finance Claire Berthier
UBS Asset Management Kariinne Laneace
United Church Funds Charles Buck
USSS Daniel Summerfield
Valori Asset Management Giancarlo Fragomeno
Vancity Investment Management Kelly Hirsch
Varma Mutual Pension Insurance Company Kaisa Ojainmaa
Vontobel Natalia Ernst
WHEB Asset Management Seb Beloe
Zevin Asset Management Pat Miguel Tomaino
Zürcher Kantonalbank Eve Morelli

Updated June 2021